Spondyloarthropathies
Feature
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Experts in rheumatology, dermatology, and gastroenterology assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic...
From the Journals
Methotrexate does not impair sperm quality, small study finds
The findings provide reassurance that men can start methotrexate therapy while actively pursuing parenthood.
Feature
After Yusimry’s steep discount, little clarity on future adalimumab biosimilar pricing
SmithRx, which bills itself as “next-generation pharmacy benefits management,” announced that it will offer Yusimry to its members at a discount...
Conference Coverage
High-intensity interval training has sustainable effects in patients with inflammatory arthritis
Patients in a randomized trial improved their cardiorespiratory fitness, but the positive response did not coincide with changes in pain or...
Conference Coverage
Early axial spondyloarthritis diagnosis in referred patients remains stable in most
Patients who are diagnosed with axial spondyloarthritis after referral to a rheumatologist for chronic back pain most often keep that diagnosis,...
Feature
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis
Musculoskeletal symptoms identified in some patients treated with dupilumab for atopic dermatitis could help further understanding of how...
Conference Coverage
Two biologics show no difference in axial spondyloarthritis radiographic progression over 2 years
This study represents the first head-to-head trial comparing the effects of two biologics in axial spondyloarthritis, in this case in patients at...
Conference Coverage
AxSpA remission on TNFi seen in half of patients with comorbid IBD
Those who had IBD for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axSpA remission...
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
Conference Coverage
AxSpA effects may be more severe for Black patients
A higher percentage of Black patients had elevated erythrocyte sedimentation rate, C-reactive protein, and hip involvement in a small study. Black...
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.